Azenta, the lab equipment provider, reported revenue up 6% to $159m for Q4 FY25. EPS advanced to 21c, topping estimates of 19c on multiomics growth. Adjusted EBITDA margin expanded 230bps to 13%. FY26 revenue guidance 3–5% organic growth. Shares surged over 10%.